CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for April 2023. CENTOGENE representatives will be attending events in Spain, the U.S., and Germany and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.
Continue reading here:
CENTOGENE to Participate in Upcoming Conferences in April
Related Post
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - October 6th, 2024
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - October 6th, 2024
- Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer - October 6th, 2024
- Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - October 6th, 2024
- BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - October 6th, 2024
- NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - October 6th, 2024
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - October 6th, 2024
- Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - October 6th, 2024
- Major Shareholder Announcement - October 6th, 2024
- Altamira Therapeutics Provides Update on Nasdaq Listing - October 6th, 2024
- Trevena Announces Receipt of Nasdaq Delisting Notification - October 6th, 2024
- Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - October 6th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 6th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - October 6th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - October 6th, 2024
- Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda - October 6th, 2024
- Celldex Therapeutics to Present at Upcoming Investor Conferences - September 13th, 2024
- NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences - September 13th, 2024
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 13th, 2024
- One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations - September 13th, 2024
- Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company - September 13th, 2024
- Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs - September 13th, 2024
- Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - September 13th, 2024
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in... - September 13th, 2024
- Immunocore to present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros - September 13th, 2024
- Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC - September 13th, 2024
- XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - September 13th, 2024
- Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- MBX Biosciences Announces Pricing of Initial Public Offering - September 13th, 2024
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy - September 13th, 2024
- Valneva Announces the Success of its Private Placement Raising approximately €60 Million - September 13th, 2024
- Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO - September 13th, 2024
- NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - August 25th, 2024
- Burning Rock Reports Second Quarter 2024 Financial Results - August 25th, 2024
- Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin... - August 25th, 2024
- Vistin Pharma ASA: Second quarter and first half 2024 financial results - August 25th, 2024
- PCI Biotech: Invitation to first half interim 2024 results presentation - August 25th, 2024
- AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema - August 25th, 2024
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - August 25th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 25th, 2024
- CytoDyn Engages Leading CRO For Phase II Inflammation Trial - August 25th, 2024
- OKYO Pharma CEO Interview to Air on Bloomberg TV - August 25th, 2024
- Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark - August 25th, 2024
- Wendy Vlieks Appointed as President of The Genome Partnership, Succeeding Leisa Zigman - August 25th, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 25th, 2024
- Thermo Scientific™ VisionMate™ HSX High Speed Barcode Reader Integrates with eLabNext Platform - August 25th, 2024
- Eyenovia Announces Closing of Public Offering - August 25th, 2024
- NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences - August 25th, 2024
- SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome - August 25th, 2024
- ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics - August 25th, 2024
- HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction - August 25th, 2024
- Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - August 25th, 2024
- Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - August 7th, 2024
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 - August 7th, 2024
- Cytek Biosciences Reports Second Quarter 2024 Financial Results - August 7th, 2024
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results - August 7th, 2024
- Supernus Announces Second Quarter 2024 Financial Results - August 7th, 2024
- Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights - August 7th, 2024
- Certara Reports Second Quarter 2024 Financial Results - August 7th, 2024
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- Cellectis Provides Financial Results for the Second Quarter 2024 - August 7th, 2024
- UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - August 7th, 2024
- Travere Therapeutics to Present at Upcoming Investor Conferences - August 7th, 2024
- ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 - August 7th, 2024
- Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib - August 7th, 2024
- BioVie Inc. Announces Reverse Stock Split - August 7th, 2024
- Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 - August 7th, 2024
- Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024 - August 7th, 2024
- Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - August 7th, 2024
- Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer - August 7th, 2024